Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis.
Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis.
复制标题
CD11b 表达水平对急性髓系白血病患者的预后价值：荟萃分析
DOI：
10.1371/journal.pone.0135981
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Xu S;Li X;Zhang J;Chen J
背景CD 11b对急性髓系白血病（AML）患者预后价值的研究结果不一致。进行了最新的荟萃分析，以评估CD 11b表达水平对AML患者的预后价值。方法计算机检索PubMed、Embase、科克伦图书馆、Web of Science和中国生物医学文献数据库（CBM），检索CD 11 b表达水平与AML患者预后关系的相关研究。使用Revman 5.3和Stata 11.0计算总生存期（OS）和无病生存期（DFS）的合并风险比（HR）和95%置信区间（CI），以及完全缓解率（CRR）的合并比值比（OR）和95% CI。结果共纳入13篇文献，2619例患者。荟萃分析结果显示，CD 11b阳性与较低的CRR相关（OR = 0.44; 95% CI，0.25-0.79; p = 0.006）和OS更短（HR = 0.66; 95%CI，0.55-0.80; p < 0.0001），但不影响DFS（HR = 0.67; 95%CI，0.31-1.48; p = 0.32）。按种族、CD 11b阳性临界值、治疗、亚型和样本制备方法进行的亚组分析显示，这些因素与AML患者CD 11b表达水平的预后价值之间无显著相互作用。敏感性分析结果与主要荟萃分析结果一致。结论CD 11b阳性可预测AML患者预后不良。因此，CD 11b表达水平可能被认为是AML患者的预后生物标志物。
Background Study results on the prognostic value of CD11b for acute myeloid leukemia (AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the prognostic value of CD11b expression level for AML patients. Methods Electronic databases including PubMed, Embase, Cochrane Library, Web of Science and Chinese BioMedical Literature Database (CBM) were searched to identify studies that investigated the association between CD11b expression level and prognosis of AML patients. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95% CI for complete remission rate (CRR) were calculated using Revman 5.3 and Stata 11.0. Results 13 total studies with 2619 patients were included in this meta-analysis. Results of the meta-analysis showed that CD11b positivity was associated with lower CRR (OR = 0.44; 95% CI, 0.25–0.79; p = 0.006) and shorter OS (HR = 0.66; 95% CI, 0.55–0.80; p < 0.0001), but did not affect DFS (HR = 0.67; 95% CI, 0.31–1.48; p = 0.32). Subgroup analysis by ethnicity, cut-off value for CD11b positivity, treatment, subtype and sample preparation method showed no significant interaction between these factors with the prognostic value of CD11b expression level for AML patients. Sensitivity analysis yielded consistent results with the main meta-analysis. Conclusion CD11b positivity could predict a poor prognosis for AML patients. Thus, CD11b expression level might be considered a prognostic biomarker for AML patients.